Recently, using a cohort of 21 patients with metastatic gastric cancer from the Samsung Medical Center, we developed a model named IMmunotherapy Against GastrIc Cancer (IMAGiC) score, based on the expression of a four-gene signature and PD-L1 combined positive score (CPS), that predicts response to pembrolizumab [10]. This evidence concerns the gene CD274 and gastric cancer.